Compare Synopsys, Inc. (SNPS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Synopsys, Inc. trades at $412.4 (market cap $78.68B), while Zimmer Biomet Holdings Inc trades at $96.75 (market cap $18.55B). The key difference: Synopsys, Inc. is far larger — about 4.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | ZBH | |
|---|---|---|
Market Cap | $78.68B | $18.55B |
Sector | Technology | Health |
52-Week High | $625.80 | $107.71 |
52-Week Low | $372.33 | $79.58 |
Enterprise Value | $87.04B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $413.78, up 0.51% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E of 94.03, P/S of 8.68) but maintains strong gross margins of 73.47%. Recent news highlights AI-driven growth from the Ansys acquisition and partnerships with AMD and Microsoft, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. Earnings growth and AI adoption in chip design are key catalysts, yet investors should monitor margin sustainability and debt levels amid expansion.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
